文献库搜索 | GeneLibs

van den Ende(NS),Smid(M),Martens(JWM),Debe... NPJ Breast Cancer 2026-05-13

...BRCA1/2, PIK3CA, and RB1, have been associated with favorable responses to targeted therapeutics in clinical trials. Mor...

Huang(L),Yang(Y),Dai(L),Zhou(J),Shao(J),Qi... Sci Rep 2026-05-12

...BRCA1/2 mutations, resistance inevitably emerges in TNBC patients. Ataxia telangiectasia and Rad3-related (ATR) protein ...

Lkhoyaali(S),Ghizlane(C),Batlamous(B),Efou... J Cancer Res Clin Oncol 2026-05-13

...BRCA1/2, and VEGF.56 CONCLUSION: Morocco has transitioned from case-series oncology research to integrated molecular-epi...

Mediavilla-Medel(P),García-Simón(N),Gonzál... Cancers (Basel) 2026-04-24

...BRCA1/2 and ATM mutations, guiding targeted therapies, and enabling real-time monitoring of treatment response and resis...

De Marco(C),Rocca(V),Migliozzi(S),Venezian... Cancers (Basel) 2026-04-28

...BRCA1/2) exhibited significantly worse survival compared with both BRCA1/2-mutated cases and the overall cohort. Conclus...

Li(X),Duan(Y),Zhou(J),Yu(P) Plants (Basel) 2026-04-28

...BRCA1 GENE1 (NBR1) is one of the best-characterized. NBR1 mediates the selective turnover of ubiquitinated or stress-dam...

De Bonis(M),Iapicca(P),De Paolis(E),Brisig... Int J Mol Sci 2026-04-29

...BRCA1/2 (BRCA) genes in ovarian cancer (OC). We evaluated the performance of a high-resolution algorithm integrated into...

Palikhe(S),Qiao(L),Kutz(C),Liang(X),Dhoraj... bioRxiv 2026-02-26

...Brca1 +/- mice. These findings identify Brca1 heterozygosity as a modifier of metabolic disease risk, expanding BRCA1 bi...

Latif(M),Mazhar(S),Tasleem(M),Alqurashi(A)... Drug Des Devel Ther None

...BRCA1/2 in BC and OC, highlighting key discovery milestones and providing an overview of available PARP inhibitors (PARP...

Vascotto(IA),Catalano(M),Venturini(J),Cala... Front Oncol None

...BRCA1/2 (three BRCA2, two BRCA1), and one patient with concurrent PALB2. Median age at therapy initiation was 70 years (...